Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Market Cap | Shares Float | Float Held by Institutions % | Shares Outstanding | Shares Authorized | Institutional Own % | ADS Representation |
|---|---|---|---|---|---|---|
| 205.18 M | 135.16 M | 1.70% | 162.84 M | 298.00 M | 1.70% | American Depositary Shares, each representing five Ordinary Shares |
| Date of Short Interest by FINRA | Shares Sold Short | Short Float % | Insider Own % | Number Institutions Holding Shares |
|---|---|---|---|---|
| 31-Aug-2023 | 1.11 M | 0.96% | 0.00% | 59 |
| Financial Doc Link | Date of Doc | Cash Equivalents | Cash Flow Operating Activities (monthly) | Operating Expenses (monthly) |
|---|---|---|---|---|
| 20-F | 31-Aug-2023 | $71.32 M | $0.62 M | Unavailable |
| Current Assets | Current Liabilities | Working Capital | Total Assets | Total Liabilities | Total Revenues (12 mo) |
|---|---|---|---|---|---|
| $81.66 M | $41.98 M | $39.68 M | $669.41 M | $167.58 M | $7.50 M |
Dilutive convertible shares can impact a stock's price by increasing the number of outstanding shares, potentially reducing the value of existing shares and decreasing the stock price.
Stock Warrants can increase share count when exercised. This dilutions affects earnings per share and potentially reduces stock value and impacting investments.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Sign up to see if this company has any automatic shelf registrations
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Sign up to see if this company has any shelf registrations pending effect
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements pending effect
Company current reports can impact investments by providing important information on material events and changes at the company, affecting the stock price and potential for gains or losses.